ArticleImmunology2003
Allergen-induced fluctuation in CC chemokine receptor 3 expression on bone marrow CD34+ cells from asthmatic subjects: significance for mobilization of haemopoietic progenitor cells in allergic inflammation.
Article in Immunology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 88 citations in OpenAlex.
- Severe Eosinophilic Asthma: From Immunopathology to Pharmacological Treatment.Journal of clinical medicine · 2026Review
- Bone marrow CCR3 dictates eosinophil lineage commitment of CD34⁺ progenitors to orchestrate allergic rhinitis: A composite study.PloS one · 2026Article
- Pathobiology and Regulation of Eosinophils, Mast Cells, and Basophils in Allergic Asthma.Immunological reviews · 2025Review
- Platelets Independently Recruit into Asthmatic Lungs and Models of Allergic Inflammation via CCR3.American journal of respiratory cell and molecular biology · 2021Article
- Review
- Article
- Severe Eosinophilic Asthma.Journal of clinical medicine · 2019Review
- CD26 and Asthma: a Comprehensive Review.Clinical reviews in allergy & immunology · 2019Review
- Bone marrow type 2 innate lymphoid cells: a local source of interleukin-5 in interleukin-33-driven eosinophilia.Immunology · 2018Article
- Airway remodeling in asthma: what really matters.Cell and tissue research · 2017Review
- The binary toxin CDT enhances Clostridium difficile virulence by suppressing protective colonic eosinophilia.Nature microbiology · 2016Article
- Eosinophil differentiation in the bone marrow is promoted by protein tyrosine phosphatase SHP2.Cell death & disease · 2016Article
- Clinical usefulness of mepolizumab in severe eosinophilic asthma.Therapeutics and clinical risk management · 2016Review
- Pathogenetic and prognostic roles of bloodborne fibrocytes in asthma.Journal of Zhejiang University. Science. B · 2015Review
- In situ hematopoiesis: a regulator of TH2 cytokine-mediated immunity and inflammation at mucosal surfaces.Mucosal immunology · 2015Review
- Hematopoietic stem and progenitor cells in inflammation and allergy.Frontiers in immunology · 2013Review
- Anti-interleukin-5 therapy in severe asthma.European respiratory review : an official journal of the European Respiratory Society · 2013Review
- Differentiation of innate type-2 effector cells.Immunologic research · 2013Review
- PTP1B deficiency exacerbates inflammation and accelerates leukocyte trafficking in vivo.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- Transcriptional Changes of Blood Eosinophils After Methacholine Inhalation Challenge in Asthmatics.Genomics insights · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
Abstract
There is increasing evidence that primitive progenitors migrate from the bone marrow (BM) via the peripheral circulation to tissue sites where they undergo in situ differentiation to provide a continued source of effector cells, such as eosinophils, during an allergic inflammatory response. To study mechanisms of progenitor cell mobilization in allergic reactions, we investigated fluctuations in the expression of the eotaxin receptor, CC chemokine receptor 3 (CCR3), on CD34+ cells from stable asthmatics following allergen (i.e. antigen) challenge. BM aspirates were taken from seven early responder (ER) and 10 dual responder (DR) asthmatics who, following antigen challenge developed only an early bronchoconstrictor response and an early and late- bronchoconstrictor response, respectively. Expression of CCR3 was detected on primitive (CD34+ cells) and eosinophil-lineage committed progenitors (CD34+ interleukin-5 receptor alpha-subunit+ cells) by flow cytometry and confirmed by co-localization of CCR3 messenger RNA to CD34 immunopositive cells using in situ hybridization. When preantigen levels were compared to 24-hr postantigen levels, significant increases in BM CD34+ CCR3+ cells were detected in DR, who also developed a significant sputum and blood eosinophilia and increased methacholine airway responsiveness. In contrast, a significant attenuation of BM CD34+ CCR3+ cells was observed in ER. In a dose-dependent manner eotaxin, but not interleukin (IL)-5, stimulated CD34+ progenitor cell migration in vitro. This migrational response to eotaxin was abrogated by anti-CCR3 monoclonal antibody and primed by preincubation with IL-5. We propose that fluctuations in CCR3 expression on human BM CD34+ cells may facilitate chemokine-mediated progenitor cell mobilization to the peripheral circulation and the resultant development of pulmonary eosinophilia, a cardinal feature of asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.